Clinical Trial Update: Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of JKN2304 inhalation solution in patients with moderate to severe COPD has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• JKN2304 inhalation solution

Snippet

Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd | Conditions: COPD (Chronic Obstructive Pulmonary Disease), COPD | Phase 2 | Status: COMPLETED